GILEAD SCIENCES, INC.

(GILD)
  Report
Delayed Nasdaq  -  04:00 2022-07-01 pm EDT
62.36 USD   +0.89%
06/29Kite's CAR T-cell Therapy Yescarta Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Follicular Lymphoma
AQ
06/28Kite's CAR T-cell Therapy Yescarta« Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Follicular Lymphoma
BU
06/27Gilead Sciences Resubmits Application for HIV Treatment Candidate
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Most relevant news about GILEAD SCIENCES, INC.
06/29Kite's CAR T-cell Therapy Yescarta Granted European Marketing Authorization for the Tre..
AQ
06/28Kite's CAR T-cell Therapy Yescarta« Granted European Marketing Authorization for the Tr..
BU
06/27Gilead Sciences Resubmits Application for HIV Treatment Candidate
MT
06/27Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapa..
BU
06/27Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapa..
CI
06/27Gilead Sciences, Inc. - Investigational Lenacapavir Receives Positive CHMP Opinion for ..
AQ
06/27Gilead Endorses The Kigali Declaration On Preventing, Controlling and Eliminating Negle..
BU
06/24Gilead Sciences Receives Positive CHMP Opinion for HIV Drug
MT
06/24Gilead Sciences, Inc. - Treatment With Hepcludex (Bulevirtide) Meets Primary Endpoint a..
AQ
06/24Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug R..
BU
06/24Gilead Sciences, Inc. Announces Investigational Lenacapavir Receives Positive Chmp Opin..
CI
06/24Gilead Gets CHMP Backing for Lenacapavir in Multi-Drug Resistant HIV
DJ
06/23Gilead Sciences Says Phase 3 Trial of Hepatitis Drug Meets Primary Endpoint
MT
06/23Treatment With Hepcludex« (Bulevirtide) Meets Primary Endpoint and Achieves Significant..
BU
06/23Gilead Sciences, Inc. Announces Week 48 Results from the Pivotal Phase 3 Clinical Trial..
CI
More most relevant news
All news about GILEAD SCIENCES, INC.
06/29Kite's CAR T-cell Therapy Yescarta Granted European Marketing Authorization for the Tre..
AQ
06/28Kite's CAR T-cell Therapy Yescarta« Granted European Marketing Authorization for the Tr..
BU
06/27Gilead Sciences Resubmits Application for HIV Treatment Candidate
MT
06/27Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapa..
BU
06/27Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapa..
CI
06/27Gilead Sciences, Inc. - Investigational Lenacapavir Receives Positive CHMP Opinion for ..
AQ
06/27Gilead Endorses The Kigali Declaration On Preventing, Controlling and Eliminating Negle..
BU
06/24Gilead Sciences Receives Positive CHMP Opinion for HIV Drug
MT
06/24Gilead Sciences, Inc. - Treatment With Hepcludex (Bulevirtide) Meets Primary Endpoint a..
AQ
06/24Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug R..
BU
More news
News in other languages on GILEAD SCIENCES, INC.
06/27Gilead Sciences soumet à nouveau une demande pour un candidat au traitement du VIH
06/27Gilead soumet à nouveau une demande d'autorisation de mise sur le marché à la Food and ..
06/24Gilead Sciences reçoit un avis positif du CHMP pour son médicament contre le VIH
06/24Gilead Sciences, Inc. annonce que le lenacapavir expérimental a reçu un avis positif de..
06/23Gilead Sciences déclare que l'essai de phase 3 du médicament contre l'hépatite a attein..
06/23Gilead Sciences, Inc. Annonce les résultats à la 48e semaine de l'essai clinique pivot ..
06/15Les nouvelles données de Gilead Sciences soulignent que les personnes vivant avec le VI..
06/13RELIEF : nouveau désaveu aux Etats-Unis pour l'aviptadil contre la Covid-19
06/06Les données finales de l'étude de phase 3 Ascent démontrent que Trodelvy prolonge la su..
06/04Gilead Sciences, Inc. Annonce des résultats positifs de l'analyse primaire de l'étude d..
More news
Analyst Recommendations on GILEAD SCIENCES, INC.
05/23SVB Securities Initiates Gilead Sciences at Market Perform With $68 Price Target
MT
05/23ANALYST RECOMMANDATIONS : AbbVie, Amgen, Caterpillar, HP, Nike...
05/17ANALYST RECOMMENDATIONS : AMD, CarMax, Gilead, J.B. Hunt, Vodafone...
05/17Piper Sandler Adjusts Gilead Sciences' Price Target to $69 From $73, Maintains Neutral ..
MT
05/13UBS Adjusts Gilead Sciences Price Target to $64 From $65, Maintains Neutral Rating
MT
More recommendations
Press releases
06/29Kite's CAR T-cell Therapy Yescarta Granted European Marketing Authorization for the Tre..
AQ
06/28Kite's CAR T-cell Therapy Yescarta« Granted European Marketing Authorization for the Tr..
BU
06/27Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapa..
BU
06/27Gilead Sciences, Inc. - Investigational Lenacapavir Receives Positive CHMP Opinion for ..
AQ
06/27Gilead Endorses The Kigali Declaration On Preventing, Controlling and Eliminating Negle..
BU
More press releases
Official Publications
Upcoming event on GILEAD SCIENCES, INC.